These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1140 related items for PubMed ID: 28414714

  • 21. Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease.
    David C, Divard G, Abbas R, Escoubet B, Chezel J, Chauveheid MP, Rouzaud D, Boutten A, Papo T, Dehoux M, Sacre K.
    Scand J Rheumatol; 2020 Jan; 49(1):33-37. PubMed ID: 31161842
    [Abstract] [Full Text] [Related]

  • 22. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
    Fischer K, Brzosko M, Walecka A, Ostanek L, Sawicki M.
    Pol Arch Med Wewn; 2007 Jan; 117 Suppl():13-7. PubMed ID: 18778013
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. SLE, atherosclerosis and cardiovascular disease.
    Frostegård J.
    J Intern Med; 2005 Jun; 257(6):485-95. PubMed ID: 15910552
    [Abstract] [Full Text] [Related]

  • 26. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.
    Rahman M, Sing S, Golabkesh Z, Fiskesund R, Gustafsson T, Jogestrand T, Frostegård AG, Hafström I, Liu A, Frostegård J.
    Clin Immunol; 2016 May; 166-167():27-37. PubMed ID: 27102765
    [Abstract] [Full Text] [Related]

  • 27. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus.
    Cederholm A, Svenungsson E, Stengel D, Fei GZ, Pockley AG, Ninio E, Frostegård J.
    Arthritis Rheum; 2004 Sep; 50(9):2869-76. PubMed ID: 15457454
    [Abstract] [Full Text] [Related]

  • 28. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus.
    Bruce IN.
    Rheumatology (Oxford); 2005 Dec; 44(12):1492-502. PubMed ID: 16234277
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus.
    Liu A, Rahman M, Hafström I, Ajeganova S, Frostegård J.
    Lupus; 2020 Jul; 29(8):825-835. PubMed ID: 32479241
    [Abstract] [Full Text] [Related]

  • 32. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.
    Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG.
    Rheumatology (Oxford); 2018 Dec 01; 57(12):2158-2166. PubMed ID: 30102390
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response.
    Conti F, Spinelli FR, Alessandri C, Pacelli M, Ceccarelli F, Marocchi E, Montali A, Capozzi A, Buttari B, Profumo E, Sorice M, Arca M, Valesini G, Riganò R.
    Arterioscler Thromb Vasc Biol; 2014 Mar 01; 34(3):661-8. PubMed ID: 24436371
    [Abstract] [Full Text] [Related]

  • 35. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.
    Jiménez S, García-Criado MA, Tàssies D, Reverter JC, Cervera R, Gilabert MR, Zambón D, Ros E, Bru C, Font J.
    Rheumatology (Oxford); 2005 Jun 01; 44(6):756-61. PubMed ID: 15757967
    [Abstract] [Full Text] [Related]

  • 36. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years.
    Ajeganova S, Hafström I, Frostegård J.
    Lupus Sci Med; 2021 Feb 01; 8(1):. PubMed ID: 33547230
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus.
    Frostegård J, Hellström C, Nilsson P, Frostegård AG, Ajeganova S.
    Lupus; 2018 Sep 01; 27(10):1670-1678. PubMed ID: 30041579
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.